National Lipid Association and Elsevier announce publishing partnership plan

November 02, 2006

New York, 2 November, 2006 -- Elsevier, world-leading scientific, technical and medical publisher, is pleased to announce its new partnership with the NLA - National Lipid Association, the leading society for medical doctors and other health care professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism.

In March 2007, the Association and Elsevier will commence publication of the Journal of Clinical Lipidology as the official publication of the Association. Dr. W. Virgil Brown, who is Charles Howard Candler Professor of Internal Medicine at Emory University School of Medicine, and Chief of Medicine at the Atlanta VAMC, will serve as Founding Editor-in-Chief of the new journal.

Journal of Clinical Lipidology will present scientific and clinical research from every field involved in lipids and clinical lipidology. The specialty of "lipidology," a multidisciplinary branch of medicine focusing on lipid and lipoprotein metabolism and their associated disorders, is still in its infancy and continues to evolve with the field of medicine as a whole. The field is growing rapidly in response to demographic trends that place an increasing number of Americans at risk for coronary heart disease (CHD) and epidemic levels of obesity concurrent with a surge in new cases of diabetes mellitus.

In addition to presenting peer-reviewed research, reviews, and editorials, the new journal will occasionally publish the Association's consensus reports, dyslipidemia and cholesterol reduction guidelines, and, among other official reports, the plenary lecture from the National Lipid Association's scientific sessions.

According to Dr. Brown, "there has been no journal to date that serves the entire clinical lipidology field, targeted specifically at practitioners, clinical academic researchers, and trainees, all of whom are integral components of the diagnosis and treatment of patients with lipid disorders and cardiovascular disease, this journal will incisively address this challenge."

Beginning in March 2007, the full-text of each issue of Journal of Clinical Lipidology will be available online to National Lipid Association members and individual subscribers through its customized website (, as well as through Elsevier's online subscription service, ScienceDirect ( for institutional subscriptions.

"The leadership of the National Lipid Association are convinced that it is essential for our organization to establish its own forum to address the needs and concerns of the international lipidology community," said James M. McKenney, PharmD, President of the National Lipid Association. "Our new partnership with Elsevier, and the upcoming launch of Journal of Clinical Lipidology, represents a major step forward in meeting the Association's goal of international leadership in science, education, and advocacy for the diagnosis and treatment of disease in the area of clinical lipidology.

"Our new journal will cover the gamut of topics in clinical lipidology today, addressing the common challenges of physicians, nurses, dieticians and pharmacists who help manage patients with lipid disorders and cardiovascular disease." "Our mission", added Dr. Brown, "is to help reduce deaths related to high, bad LDL cholesterol and further, the journal's scope will be to enhance the practice of lipid management in clinical medicine and to reduce the morbidity and mortality associated with atherosclerotic disease. Ultimately, our goal will be to educate, advocate, and perhaps, at times, even to pontificate."
For information on subscribing or submitting manuscripts to Journal of Clinical Lipidology visit

About the National Lipid Association
The National Lipid Association (NLA) ( is a non-profit membership association that serves physicians, nurses, pharmacists and dieticians who help manage patients with lipid disorders and cardiovascular disease. The NLA represents more than 2,000 members in the United States and provides continuing medical education for physicians and other healthcare professionals to advance professional development and attain certification in clinical lipidology. The NLA's public health mission is to help reduce deaths related to high cholesterol.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (, MD Consult (, Scopus (, bibliographic databases, and online reference works.

Elsevier ( is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


Related Cardiovascular Disease Articles from Brightsurf:

Changes by income level in cardiovascular disease in US
Researchers examined changes in how common cardiovascular disease was in the highest-income earners compared with the rest of the population in the United States between 1999 and 2016.

Fighting cardiovascular disease with acne drug
Researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy - a leading cause of heart failure - and identified a potential treatment for it: a drug already used to treat acne.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Dilemma of COVID-19, aging and cardiovascular disease
Whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19) is discussed in this article.

Air pollution linked to dementia and cardiovascular disease
People continuously exposed to air pollution are at increased risk of dementia, especially if they also suffer from cardiovascular diseases, according to a study at Karolinska Institutet in Sweden published in the journal JAMA Neurology.

New insights into the effect of aging on cardiovascular disease
Aging adults are more likely to have - and die from - cardiovascular disease than their younger counterparts.

Premature death from cardiovascular disease
National data were used to examine changes from 2000 to 2015 in premature death (ages 25 to 64) from cardiovascular disease in the United States.

Ultrasound: The potential power for cardiovascular disease therapy
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Despite the ACA, millions of Americans with cardiovascular disease still can't get care
Cardiovascular disease (CVD) is the leading cause of death for Americans, yet millions with CVD or cardiovascular risk factors (CVRF) still can't access the care they need, even years after the implementation of the Affordable Care Act (ACA).

Excess weight and body fat cause cardiovascular disease
In the first Mendelian randomization study to look at this, researchers have found evidence that excess weight and body fat cause a range of heart and blood vessel diseases (rather than just being associated with it).

Read More: Cardiovascular Disease News and Cardiovascular Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to